Lp(a): The Genetic Cardiovascular Risk You Measure Only Once

Lipoprotein(a), or Lp(a), is a cholesterol particle whose blood concentration is set roughly 90% by genetics and stays stable from childhood to old age. About one in five people carries an elevated level, causally linked to a higher risk of heart attack, stroke and aortic valve narrowing, independently of LDL cholesterol (PubMed). Because that number barely moves over a lifetime, a single measurement is enough to know where you stand.

It is a singularity in the landscape of cardiovascular markers. LDL, blood sugar and blood pressure fluctuate with diet, weight and age, and are therefore monitored regularly. Lp(a) is written into the genome. You measure it once, and you know your terrain for life.

Yet it rarely appears on a routine lab order.

An LDL Particle With a Genetic Passenger

Lp(a) resembles an LDL particle (the "bad cholesterol"), with one difference: an extra protein, apolipoprotein(a), is attached to it by a stable chemical bond. That passenger changes everything.

Apolipoprotein(a) bears a striking structural resemblance to plasminogen, a protein involved in dissolving blood clots. This similarity may let it interfere with fibrinolysis (the natural mechanism that breaks down clots), adding a tendency toward clotting to its purely lipid effect. Lp(a) also carries oxidized phospholipids, powerful inflammatory signals for the arterial wall (PubMed).

It thus combines three harmful mechanisms. It deposits cholesterol in the artery wall like LDL. It promotes clot formation. And it sustains local inflammation. This triple action explains its contribution to atherosclerosis, the buildup of plaque in the arteries, and to calcific aortic stenosis, the progressive narrowing of the aortic valve (PubMed).

Why a Single Measurement Lasts a Lifetime

Lp(a) level is determined 70-90% by a single gene, the LPA gene (PubMed). The variability comes mainly from the number of copies of a repeated motif within that gene: the fewer the copies, the smaller the particle produced and the more the liver secretes. This determinism is set at conception and does not fade.

In practice, the concentration stabilizes around age five and varies very little thereafter. Neither weight loss, nor exercise, nor dietary changes shift it appreciably. This is the exact opposite of LDL, sensitive to the slightest dietary adjustment.

That stability has a direct practical consequence. Unlike other lipid markers, Lp(a) calls for no repeat monitoring. European guidelines recommend measuring it at least once in every adult's lifetime (PubMed). A single value is enough to place the risk durably.

One measurement subtlety conditions the reliability of the result: the unit. Lp(a) can be reported by mass (mg/dL) or by particle number (nmol/L). Because the size of apolipoprotein(a) varies widely between individuals, the mass measurement can over- or underestimate the real number of particles. Recent consensus statements recommend the nmol/L unit and advise against any conversion between the two using a fixed factor (PubMed).

A Number Lifestyle Barely Moves

Here is the paradox that makes Lp(a) so disconcerting: it is a major, causal cardiovascular risk factor, and yet no lifestyle change truly lowers it.

Statins, the cornerstone of cholesterol lowering, are ineffective here: they leave Lp(a) unchanged, or even raise it slightly. Diet and physical activity have only a marginal effect. PCSK9 inhibitors, a class of lipid-lowering drugs, cut it by roughly 20 to 25%, without that reduction having been specifically validated as beneficial. Only apheresis, a filtration of the blood akin to dialysis, lowers it substantially, at the cost of a heavy procedure reserved for the most severe cases (PubMed).

The picture is shifting. Therapies targeting RNA directly (the messenger that translates the gene into protein) are in advanced development. Antisense oligonucleotides and small interfering RNAs silence the liver's production of apolipoprotein(a) and cut Lp(a) by 80 to 98% in trials (PubMed). Large trials measuring their effect on heart attacks and strokes are under way (PubMed). Their results will determine whether lowering Lp(a) actually reduces events.

What an Elevated Lp(a) Reveals, and What to Do With It

If you cannot yet act on Lp(a) itself, why measure it? Because it recalibrates the entire prevention strategy.

An elevated Lp(a) acts as a risk multiplier. It adds to the other factors without replacing them. The logical response is to tighten everything that remains modifiable, with heightened rigor: LDL cholesterol and ApoB (the number of atherogenic particles), blood pressure, blood sugar, smoking, weight (PubMed). A fixed genetic risk raises the bar on the levers you do control.

The measurement also carries a family dimension. Because Lp(a) is hereditary, a high level in one person often warrants checking first-degree relatives. A single screening can inform an entire lineage.

Finally, it explains otherwise puzzling situations: an early heart attack in someone whose lipid panel looks normal, or unexplained family cardiovascular history. In many cases, Lp(a) is the missing factor that the standard panel does not look for.

Lp(a) overturns an ingrained intuition. In preventive medicine, we readily believe that everything can be corrected through effort and discipline. This marker reminds us that part of the risk is distributed at birth, indifferent to willpower. Identifying that non-negotiable share is precisely what lets you concentrate your energy where it genuinely counts. One number, obtained once, to steer a trajectory of several decades.

Frequently asked questions

What is Lp(a), and how does it differ from LDL cholesterol?#[ + ]

Lipoprotein(a) is a particle similar to LDL, with an additional protein attached to it, apolipoprotein(a), bound by a stable chemical link. This protein gives it properties LDL lacks: it resembles plasminogen and can interfere with clot breakdown, while also carrying inflammatory signals. Lp(a) therefore combines an effect on cholesterol, on clotting, and on inflammation.

Why is Lp(a) measured only once in a lifetime?#[ + ]

Because its concentration is determined 70-90% by a single gene, the LPA gene, and stabilizes in early childhood. Unlike LDL cholesterol, it barely varies with diet, weight or age. A single value is therefore enough to classify risk durably, with no repeat monitoring needed.

Can an elevated Lp(a) be lowered?#[ + ]

Not meaningfully with current tools. Statins leave it unchanged, diet and exercise have only a marginal effect, and only apheresis (a filtration of the blood) lowers it substantially, in severe cases. Therapies targeting the gene directly cut Lp(a) by more than 80% in trials, but they remain investigational.

At what threshold is Lp(a) considered elevated?#[ + ]

The commonly used threshold is above 50 mg/dL, roughly 125 nmol/L. Risk is continuous, however: it rises progressively with concentration. Recent consensus statements recommend the nmol/L unit, which is more reliable, and advise against converting between the two units with a fixed factor.

What should you do if you find you have an elevated Lp(a)?#[ + ]

The goal is to tighten every other modifiable risk factor more strictly: LDL cholesterol, blood pressure, blood sugar, smoking, weight. Because Lp(a) is hereditary, an elevated level often warrants checking first-degree relatives. Any health decision should be made with a healthcare professional.

---

References

1. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339 (PubMed).
2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711 (PubMed).
3. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946 (PubMed).
4. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528 (PubMed).
5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188 (PubMed).
6. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853 (PubMed).
7. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382(3):244-255 (PubMed).
8. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855-1864 (PubMed).